The Globe and Mail reports in its Thursday edition that as competition intensifies for a generic version of the blockbuster drug Ozempic, Vimy Pharmaceuticals plans to produce a made-in-Canada version next year. The Globe's Chris Hannay writes that Toronto-based Vimy Pharma was founded last year by Dave Suchon and Farris Smith, two former executives in Novo Nordisk's Canadian operations. As the Danish drug maker introduced Ozempic to Canada, it quickly became the best-selling medication, generating $2.5-billion in retail sales last year -- nearly triple that of the next top drug, according to IQVIA Canada. Ozempic and Wegovy, used for diabetes and weight loss, will lose market exclusivity in January, allowing for generic versions of semaglutide. Mr. Suchon and Mr. Smith said they started Vimy Pharma to fill what they saw as a gap in domestic production and ownership of pharmaceuticals. Mr. Suchon said, "There's not a ton in the way of Big Pharma that is headquartered in Canada." He added that semaglutide was an obvious candidate to focus on as Vimy's first product. "When we were forming Vimy, we took a look around at the Canadian market, and semaglutide certainly puts his hand up as crucially important for Canadians."